Harbor Asset Planning Inc. Invests $29,000 in Pfizer Inc. $PFE

Harbor Asset Planning Inc. acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,177 shares of the biopharmaceutical company’s stock, valued at approximately $29,000.

Several other large investors also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter worth $27,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth $28,000. Horizon Financial Services LLC acquired a new position in Pfizer during the first quarter worth $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer during the first quarter worth $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $24.52 on Friday. The stock has a market cap of $139.38 billion, a P/E ratio of 13.04, a P/E/G ratio of 0.80 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a fifty day moving average price of $24.89 and a two-hundred day moving average price of $24.12. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.36.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley reduced their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.